Evidence map›Paper›PMID 29390051›Full record

ArticleEuropean heart journal2018

Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study.

Carolyn S P Lam, Greg D Gamble, Lieng H Ling, David Sim, Kui Toh Gerard Leong, Poh Shuan Daniel Yeo, Hean Yee Ong, Fazlur Jaufeerally, Tze P Ng, Vicky A Cameron and 6 more

2 registry-linked trialsOpen access · bronzeAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in European heart journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 147 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
147citing papers in PubMed, 7 pooled it
21.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05727423 unknown statusnot on this mapstarted 2021, after this paper: background citation

Safety and Efficacy of Dapagliflozin in the Treatment of Heart Failure in Non-diabetic Egyptian Patients

TypeobservationalSponsorHelwan UniversityRan2021 to 2024Enrolled45ConditionsHeart Failure
NCT06455878 narecruitingnot on this mapstarted 2024, after this paper: background citation

The Impact of Dietary Management Applet for Weight Reduction in Obese Heart Failure Patients: a Multicenter, Single-blind Randomized Controlled Trial

TypeinterventionalSponsorHeart Health Research CenterRan2024 to 2026Enrolled830ConditionsHeart Failure, Overweight and Obesity, Weight Loss, Heart Failure With Reduced Ejection FractionArmsFull usage of diet management app group and with the full usage of an intelligent weight scale, Limited usage of diet management app group and with the limited usage of an intelligent weight scale
3 · Its place in the literature

Who cites it

147 citing papers in PubMed, 7 syntheses or guidelines pooled it, 277 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Article
  14. Review
  15. Is Ergothioneine an Important Source of Plasma TrimethylamineAntioxidants (Basel, Switzerland) · 2026
    Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Observational

87 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 2 countries.

Carolyn S P LamCardiovascular Research Institute, National University Health System, 1E Kent Ridge Road, Singapore 119228.
Greg D GambleHeart Health Research Group, University of Auckland, Park Road, Grafton, Auckland 1023, New Zealand.
Lieng H LingCardiovascular Research Institute, National University Health System, 1E Kent Ridge Road, Singapore 119228.
David SimNational Heart Centre Singapore and Duke-National University of Singapore, 5 Hospital Drive, Singapore 169609.
Kui Toh Gerard LeongChangi General Hospital, 2 Simei Street 3, Singapore 529889.
Poh Shuan Daniel YeoTan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433.
Hean Yee OngKhoo Teck Puat Hospital, 90 Yishun Central, Singapore 768828.
Fazlur JaufeerallySingapore General Hospital, Outram Road, Singapore 169608.
Tze P NgYong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road Singapore, Singapore 119228.
Vicky A CameronChristchurch Heart Institute, University of Otago, 2 Riccarton Avenue, Christchurch 8011, New Zealand.
Katrina PoppeHeart Health Research Group, University of Auckland, Park Road, Grafton, Auckland 1023, New Zealand.
Mayanna LundMiddlemore Hospital, 100 Hospital Road, Otahuhu, Auckland 2025, NZ.
Gerry DevlinWaikato Hospital, Pembroke Street, Hamilton 3204, New Zealand.
Richard TroughtonChristchurch Heart Institute, University of Otago, 2 Riccarton Avenue, Christchurch 8011, New Zealand.
A Mark RichardsCardiovascular Research Institute, National University Health System, 1E Kent Ridge Road, Singapore 119228.
Robert N DoughtyHeart Health Research Group, University of Auckland, Park Road, Grafton, Auckland 1023, New Zealand.
University of Auckland · NZNational University Health System · SGNational University of Singapore · SGUniversity of Otago · NZChangi General Hospital · SGKhoo Teck Puat Hospital · SGMiddlemore Hospital · NZNational Heart Centre Singapore · SGSingapore General Hospital · SGTan Tock Seng Hospital · SGWaikato Hospital · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Whether prevalence and mortality of patients with heart failure with preserved or mid-range (40-49%) ejection fraction (HFpEF and HFmREF) are similar to those of heart failure with reduced ejection fraction (HFrEF), as reported in some epidemiologic studies, remains highly controversial. We determined and compared characteristics and outcomes for patients with HFpEF, HFmREF, and HFrEF in a prospective, international, multi-ethnic population. Methods and results: Prospective multi-centre longitudinal study in New Zealand (NZ) and Singapore. Patients with HF were assessed at baseline and followed over 2 years. The primary outcome was death from any cause. Secondary outcome was death and HF hospitalization. Cox proportional hazards models were used to compare outcomes for patients with HFpEF, HFmrEF, and HFrEF. Of 2039 patients enrolled, 28% had HFpEF, 13% HFmrEF, and 59% HFrEF. Compared with HFrEF, patients with HFpEF were older (62 vs. 72 years), more commonly female (17% vs. 48%), and more likely to have a history of hypertension (61% vs. 78%) but less likely to have coronary artery disease (55% vs. 41%). During 2 years of follow-up, 343 (17%) patients died. Adjusting for age, sex, and clinical risk factors, patients with HFpEF had a lower risk of death compared with those with HFrEF (hazard ratio 0.62, 95% confidence interval 0.46-0.85). Plasma (NT-proBNP) was similarly related to mortality in both HFpEF, HFmrEF, and HFrEF independent of the co-variates listed and of ejection fraction. Results were similar for the composite endpoint of death or HF and were consistent between Singapore and NZ. Conclusion: These prospective multinational data showed that the prevalence of HFpEF within the HF population was lower than HFrEF. Death rate was comparable in HFpEF and HFmrEF and lower than in HFrEF. Plasma levels of NT-proBNP were independently and similarly predictive of death in the three HF phenotypes. Trial Registration: Australian New Zealand Clinical Trial Registry (ACTRN12610000374066).

Indexed as

AgedAged, 80 and overAge FactorsBiomarkersCohort StudiesEchocardiographyFemaleFollow-Up StudiesHeart FailureHospitalizationHumansMaleMiddle AgedNatriuretic Peptide, BrainNew ZealandPeptide FragmentsBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)

Identifiers

PMID29390051
OpenAlexW2790189896

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.